Immunic (IMUX) Aktie Kurs
Immunic Kurs
Analytikernes mediankursmål er 20,50 USD, hvilket er over den aktuelle kurs med 155,0 %. Af 19 analytikere anbefaler 18 køb — den samlede vurdering er Køb.
Immunic aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Immunic aktie og aktieanalyse
Hyppigt stillede spørgsmål om Immunic-aktien
Immunic Inc is primarily present in the United States.
Immunic Inc represents a strong commitment to advancing the treatment of autoimmune diseases and chronic inflammatory conditions. The company's corporate philosophy is centered around pioneering innovative therapies that address unmet medical needs, backed by extensive research and development. Immunic Inc prioritizes patient-centricity, aiming to enhance quality of life through effective and safe treatment options. With a focus on excellence and scientific rigor, Immunic Inc strives to deliver groundbreaking therapies that can make a meaningful difference in patients' lives.
The business model of Immunic Inc. is focused on developing innovative therapies for chronic inflammatory and autoimmune diseases. The company aims to leverage its deep understanding of the immune system and expertise in small molecule drug development to create potential treatments that target specific diseases. Through its research and development efforts, Immunic Inc. seeks to address unmet medical needs and improve the lives of patients suffering from a range of disorders, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. By combining scientific knowledge with a patient-centered approach, the company strives to provide effective and accessible therapies in the field of immunology.
Immunic Inc is primarily active in the pharmaceutical industry.
The main competitors of Immunic Inc in the market are [insert competitor names here].
Immunic Inc. is a pharmaceutical company specializing in the development of innovative therapies for autoimmune diseases and chronic inflammatory disorders. Founded in 2016, Immunic Inc. has quickly emerged as a key player in the field. The company is focused on leveraging its expertise in small molecule drug development to address unmet medical needs. Immunic Inc. is committed to advancing its pipeline of potential treatments, utilizing a targeted approach to modulate the immune system and provide patients with novel therapeutic options. With a strong dedication to research and development, Immunic Inc. aims to make a significant impact on patients' lives and contribute to the advancement of healthcare.
Immunic Inc, a leading biopharmaceutical company, has reached several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its novel therapeutic candidate, IMU-838, in patients with relapsing-remitting multiple sclerosis. The encouraging results demonstrated its potential in reducing disease activity and progression. Additionally, Immunic Inc achieved the initiation of Phase 2 clinical trials for IMU-935, an orally available small molecule targeting chronic inflammatory and autoimmune diseases. These milestones represent the company's commitment to developing innovative therapies addressing unmet medical needs. Immunic Inc continues to advance its pipeline, striving to provide effective treatments for patients globally.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 22,13 USD for Immunic-aktien (median: 20,50 USD), svarende til +175,2 % i forhold til seneste kurs. Konsensus bygger på 19 analytikervurderinger.
19 analytikere vurderer i øjeblikket Immunic-aktien: 18 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Immunic genererer omsætning på 12,50 Mio. USD og indtjening pr. aktie på -35,92 USD.
Omregnet til den aktuelle valutakurs handles Immunic-aktien til 7,19 EUR (8,04 USD).
Immunic-aktien (IMUX) er noteret på 5 børser, herunder: NASDAQ (IMUX), Frankfurt (10VA.F), München (10VA.MU), Düsseldorf (10VA.DU).
Immunic Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of immune and inflammatory diseases.The company's business model is based on four main pillars: research and development, clinical studies, product distribution, and partnerships.
forventet-omsætningen for Immunic er 12,50 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Immunic er -432,40 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Immunic er i øjeblikket -0,22. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Immunic-aktien.
Pris-til-salgs-forholdet (P/S) for Immunic er i øjeblikket 7,74. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Immunic-aktien.
AlleAktien-kvalitetsscore for Immunic er 5/10.
ISIN for Immunic er US4525EP1011. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Immunic er A2PHD4. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Immunic er IMUX. Tickersymbolet bruges til at handle Immunic-aktier på børsen.
Immunic aktie
Immunic Peer Group
Immunic Ticker
Immunic FIGI
Alle fundamentale data om Immunic i deep dive
Vores aktieanalyse af Immunic-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Immunic. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: